Encouraging Phase 3 Results: Marstacimab for Hemophilia A or B with Inhibitors
Heme Today shared a thrilled post on LinkedIn:
”ICYMI in hemophilia reporting on Heme Today: Marstacimab from Pfizer performed impressively in a phase 3 study as tx for hemophilia A or B with inhibitors.”
To learn more, follow the link.
A phase 3 study has yielded favorable topline results for Marstacimab (HYMPAVZI), showing promising efficacy and safety in treating severe hemophilia A or B with inhibitors.
Pfizer announced the positive findings, highlighting the therapy’s potential to address an important unmet need for patients with antibodies that limit factor-based prophylaxis.
“These encouraging results demonstrate HYMPAVZI’s potential to help people living with hemophilia A or B with inhibitors, meeting an important need for patients with antibodies that neutralize most factor-based prophylactic options used to manage bleeding episodes,” commented Pfizer’s chief inflammation & immunology officer Michael Vincent, MD, PhD.
Stay updated on the latest scientific advancements in the field of hemophilia management with Hemostasis Today.
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 20, 2025, 13:23From Words to Action: David McIntosh Advocates for Investment in Lifesaving Maternal Care
-
Oct 20, 2025, 13:21Royal College of Physicians of Edinburgh: Haematology 2025 — Presentation, Prevention and Possibilities
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 21, 2025, 11:08Wolfgang Miesbach on New Real-World Data for Haemophilia B Prophylaxis
-
Oct 21, 2025, 05:54John Strouse on Hydroxyurea for Children with Sickle Cell Disease
-
Oct 20, 2025, 13:22Saleh Shamse Basha Shared New Interesting Clinical Case With Recurrent Nosebleeds and Prolonged Bleeding After Dental Extractions
-
Oct 20, 2025, 13:19Steven AR Murphy: Platelet Rich Plasma is a Regenerative Therapy
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 14, 2025, 05:26Ryan C. Heniford: Every Thrombus Prevented Is a Patient Protected
-
Oct 13, 2025, 04:48Archil Jaliashvili showcases how BHOC builds on Hemopure’s success to revolutionize surgery and care
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 21, 2025, 11:11Nana Kwame Kwabi Boateng: Grateful For The Opportunity to Serve As A SEARCH Ambassador
-
Oct 21, 2025, 05:00Sheila Cristina Ouriques Martins Is Grateful to Be Among The Legends Who Changed The Reality of Stroke Worldwide
-
Oct 21, 2025, 01:47Cathy Bliem: Yesterday, I Made My 4th Plasma Donation of 2025...
-
Oct 20, 2025, 12:40Asfand Yar Cheema: Honored to be featured in Video Journal of Hematology and Hematological Oncology
-
Oct 20, 2025, 12:25Laurent Bertoletti Highlights Evolving Role of Anticoagulation in Pulmonary Hypertension Treatment